DeepCure, a leader in developing novel, small-molecule therapeutics powered by AI and chemistry automation, announced today the closing of a $24.6 million Series A-1 financing led by IAG Capital Partners (IAG) with participation from the company’s current investors. Since its founding, DeepCure has raised over $72 million in funding.
DeepCure created a generative AI and physics-based engine to innovate the discovery of small-molecule therapies for challenging targets. The engine can map potential interaction sites on the surface of proteins and design novel, synthesizable molecules with lead-like properties. Plus, DeepCure has developed the world’s most advanced automated chemistry synthesis platform to increase tested molecules’ speed, number, and diversity.
The proceeds from the Series A-1 funding will be used to develop DeepCure’s technology further and advance its immunology and inflammation pipeline toward clinical trials.
KEY QUOTES:
“IAG Capital Partners is widely recognized for its deep understanding of technology and identifying innovations that can have the most impact. Our team will benefit from their broad experience, and we are excited to have Dr. Ehsan Jabbarzadeh join our Board of Directors. We also value the continued support of our existing investors.”
– Kfir Schreiber, CEO and Co-Founder, DeepCure
“DeepCure has achieved technical breakthroughs in AI and chemistry synthesis automation that overcome critical barriers for small molecule discovery.”
– Dr. Jabbarzadeh, Venture Partner at IAG
“These breakthroughs are pivotal to drugging a huge number of intractable targets that are known to have a central role in disease biology.”
– Alex Kash, Associate at IAG Capital Partners and board observer
“These additional proceeds will allow us to accelerate our pace, advancing DeepCure’s pipeline of first-in-class and best-in-class inflammation and immunology programs toward the clinic. The programs are especially exciting to us because we see opportunities to address the unmet needs for large numbers of patients.”
– Jason Dinges, Morningside Technology Advisory and DeepCure board member
